Loading…

Alumis Inc.ALMSCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major
Momentum laggard 1
Mkt cap
$569M
US dollars, full cap
Free float
74%
of shares outstanding
$/day
$11.8M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 6.5%
Hurdle
n/a
no reverse DCF
Next earnings
127 days
25 Mar 2027
Close · USD$4.39
1D-9.2%
1W-33.6%
1M-34.4%
3M-80.8%
6M-80.1%
YTD-55.0%
1Y-21.2%
ATR %12.1%
Beta2.07
52w lowhigh86.0% off high

What Alumis does

Employees: 224

Alumis at a glance

Size Alumis (ALMS) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $569M, the 2579th largest of 3,085 United States companies the cockpit tracks. Shares closed at $4.39 on 18 Nov 2026.

Performance Over six months the shares fell 80.1%, against -20.1% for the median peer and -2.2% for the United States market (cap-weighted) — lowest of 21 in its peer set.

Growth Revenue fell 67.3% over the last twelve months (peer median +4.6%); the operating margin is -5,374.5% (peer median 6.6%).

Valuation It trades at 23.9× enterprise value to sales against a peer median of 2.6× (3rd most expensive of 18).

Short interest Short interest is 8.5% of the free float (30 Oct 2026).

Next results Next results expected around 25 Mar 2027 (exchange calendar; dates can move).

Relative performance

5010021 May 202621 Aug 202618 Nov 2026Peer median 80ALMS 20
Six months, rebased to 100: Alumis against the median of its 20 peers (local-currency closes).

Alumis financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$7.24M$24.1M$0$0$0
Revenue growth—————
Gross profit$3.74M$20.6M-$3.15M-$1.28M-$250,000
EBITDA-$386M-$424M-$298M-$157M-$114M
Net income-$423M-$243M-$294M-$155M-$112M
Free cash flow-$321M-$370M-$257M-$134M-$110M
Capital expenditure$865,000$653,000$1.73M$4.50M$2.41M
Total debt$35.3M$36.9M$30.7M$32.6M$1.78M

Quarterly statements and history in the cockpit →

Alumis competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%-20%0%ENTX6883566005683613225647432157002393603439003850CGEM4559002688300147IMMXMOREPENLABSENORESALMS6-month return →1-month return →
Up and to the right = strong over both horizons. Alumis is the large dot.

Fundamentals: revenue growth against valuation

-50%0%+50%0×50×100×6883566005683613225647432157002393ACRS603439ZVRA4559MOREPENLABALMSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Alumis is the large dot.

Alumis competitors and peer comparison

How Alumis compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Alumis against its 20 peers (data as of 18 Nov 2026)
MeasureALMSPeer medianRank in peer set
1-month return-34.4%-11.1%2nd lowest of 21
6-month return-80.1%-20.1%lowest of 21
Distance from 52-week high-86.0%-42.1%lowest of 21
Revenue growth (TTM)-67.3%+4.6%3rd lowest of 19
Operating margin-5,374.5%6.6%lowest of 18
EV / Sales23.9×2.6×3rd most expensive of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Alumis ALMSUnited States$569M-80%-67%-5,375%23.9×n/an/a
Entera Bio ENTXUnited States$568M+163%-100%n/an/an/an/a
Jenkem Technology 688356.SSChina$563M-30%+52%11%8.7×36.4%+11.2%
Zhong Zhu Healthcare 600568.SSChina$562M-22%-6%-34%6.2×n/an/a
Beijing Tong Ren Tang Chinese Medicine 3613.HKHong Kong$577M-26%-21%32%1.9×-15.4%+2.8%
Abbisko Cayman 2256.HKHong Kong$578M-39%-83%-520%20.1×n/an/a
Oneness Biotech 4743.TWOTaiwan$580M-13%+19%-589%101.5×n/an/a
Lepu Biopharma 2157.HKHong Kong$580M-43%+47%7%4.5×n/an/a
Tianjin Lisheng Pharmaceutical 002393.SZChina$557M-24%-3%7%1.2×-5.8%+4.1%
Aclaris Therapeutics ACRSUnited States$555M-23%-59%-1,412%69.1×n/an/a
GuiZhou SanLi Pharmaceutical 603439.SSChina$583M-20%-6%5%2.6×20.9%+21.9%
Boryung 003850.KSSouth Korea$554M-13%+6%6%0.9×-3.1%+12.6%
Cullinan Therapeutics CGEMUnited States$585M-37%n/an/an/an/an/a
Zevra Therapeutics ZVRAUnited States$552M-9%+75%31%2.4×-4.9%+51.6%
Zeria Pharmaceutical 4559.TJapan$552M-12%+12%15%1.0×-12.3%+11.1%
Jinhe Biotechnology 002688.SZChina$550M-19%+7%5%1.8×1.0%+9.7%
Xiangxue Pharmaceutical 300147.SZChina$591M-41%+3%-39%3.7×50.4%-12.3%
Immix Biopharma IMMXUnited States$596M-20%n/an/an/an/an/a
Morepen Laboratories MOREPENLAB.NSIndia$542M+121%+30%11%2.2×n/an/a
JIANMIN PHARMACEUTICAL 600976.SSChina$598M-14%-2%8%0.9×-6.2%+6.5%
Senores Pharmaceuticals SENORES.NSIndia$538M+3%+40%24%7.4×n/an/a

Questions

Which companies are Alumis's closest peers?
The cockpit's peer set: Entera Bio (ENTX), Jenkem Technology (688356.SS), Zhong Zhu Healthcare (600568.SS), Beijing Tong Ren Tang Chinese Medicine (3613.HK), Abbisko Cayman (2256.HK), Oneness Biotech (4743.TWO), Lepu Biopharma (2157.HK), Tianjin Lisheng Pharmaceutical (002393.SZ).
Is Alumis expensive compared with its peers?
On ev / sales it trades at 23.9× against a peer median of 2.6×, 3rd most expensive of 18 in its peer set.
How has Alumis stock performed?
Over six months to 18 Nov 2026 the shares returned -80.1% against -20.1% for the median peer; over one year -21.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.